background
administr
convalesc
plasma
serum
hyperimmun
immunoglobulin
may
clinic
benefit
treatment
sever
acut
respiratori
infect
sari
viral
etiolog
conduct
systemat
review
exploratori
metaanalysi
assess
overal
evid
method
healthcar
databas
sourc
grey
literatur
search
juli
record
screen
protocol
elig
criteria
use
process
data
extract
risk
bia
assess
undertaken
result
identifi
studi
sar
coronaviru
infect
sever
influenza
narr
analys
reveal
consist
evid
reduct
mortal
especi
convalesc
plasma
administ
earli
symptom
onset
exploratori
post
hoc
metaanalysi
show
statist
signific
reduct
pool
odd
mortal
follow
treatment
compar
placebo
therapi
odd
ratio
confid
interv
studi
commonli
low
low
qualiti
lack
control
group
moder
high
risk
bia
sourc
clinic
methodolog
heterogen
identifi
conclus
convalesc
plasma
may
reduc
mortal
appear
safe
therapi
studi
within
context
welldesign
clinic
trial
formal
evalu
includ
treatment
middl
east
respiratori
syndrom
coronaviru
cov
infect
may
world
health
organ
inform
person
laboratoryconfirm
middl
east
respiratori
syndrom
coronaviru
merscov
infect
die
current
approach
clinic
manag
merscov
infect
center
gener
support
care
provis
critic
care
organ
support
necessari
recent
suggest
administr
convalesc
plasma
hyperimmun
immunoglobulin
yield
clinic
effect
treatment
merscov
infect
howev
numer
uncertainti
remain
clinic
cours
viral
replic
kinet
host
interact
yet
fulli
establish
furthermor
underli
evid
base
studi
vari
size
qualiti
describ
clinic
experi
treat
viral
infect
includ
due
sar
coronaviru
sarscov
spanish
influenza
avian
influenza
pandem
influenza
hereaft
influenza
conduct
systemat
review
exploratori
metaanalysi
evalu
clinic
effect
convalesc
plasma
serum
hyperimmun
immunoglobulin
treatment
sever
acut
respiratori
infect
sari
viral
etiolog
help
inform
clinic
manag
merscov
infect
systemat
review
conduct
accord
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
studi
protocol
regist
nation
institut
health
research
intern
prospect
regist
systemat
review
studi
elig
criteria
avail
elsewher
briefli
studi
popul
interest
human
subject
age
sex
hospit
sari
laboratoryconfirm
suspect
viral
etiolog
intervent
interest
convalesc
plasma
serum
hyperimmun
immunoglobulin
deriv
convalesc
plasma
compar
treatment
includ
placebo
sham
therapi
intervent
studi
compar
group
also
includ
outcom
measur
deriv
protocol
research
question
ascertain
clinic
effect
therapi
two
review
j
mj
sc
execut
search
strategi
juli
sourc
inform
search
search
construct
avail
elsewher
adapt
made
search
interfac
allow
use
complex
construct
search
record
import
endnot
softwar
thomson
reuter
san
francisco
ca
screen
manual
use
paper
record
follow
remov
duplic
entri
screen
process
follow
identifi
elig
record
sequenti
examin
titl
abstract
full
text
two
review
j
mj
sc
screen
record
provis
arbitr
third
review
c
r
b
data
collect
independ
pair
review
use
pilot
form
consensu
agreement
extract
data
item
reach
discuss
provis
arbitr
third
review
j
mj
sc
c
r
b
data
extract
form
avail
appendix
studi
protocol
risk
bia
assess
perform
outcom
measur
level
data
collect
cochran
collabor
tool
use
experiment
prospect
cohort
studi
newcastleottawa
scale
use
observ
studi
exclud
prospect
cohort
studi
tool
publish
us
agenc
healthcar
research
qualiti
use
systemat
review
record
limit
abstract
assess
pauciti
inform
contain
therein
odd
ratio
or
casefat
rate
cfr
absolut
differ
cfr
differ
mean
calcul
summari
statist
confid
interv
ci
studi
characterist
outcom
measur
tabul
recogn
framework
narr
synthesi
adopt
potenti
concern
clinic
heterogen
analys
stratifi
viral
etiolog
research
question
accord
protocol
exploratori
post
hoc
randomeffectsmodel
metaanalysi
conduct
describ
pool
mortal
irrespect
sari
etiolog
follow
treatment
convalesc
plasma
serum
use
odd
receipt
placebo
therapi
refer
result
adjust
ad
cell
conting
tabl
death
occur
expos
group
individu
studi
metaanalysi
crude
cfr
use
randomeffect
model
undertaken
statist
heterogen
ascertain
use
statist
metaanalys
abandon
reach
sensit
analys
undertaken
investig
impact
exclud
studi
patient
expos
group
public
bia
assess
construct
funnel
plot
use
egger
test
statist
analys
conduct
use
stata
softwar
version
statacorp
colleg
station
tx
except
metaanalysi
pool
proport
use
statsdirect
softwar
version
statsdirect
altrincham
unit
kingdom
statist
signific
assum
level
search
process
yield
record
figur
sift
uniqu
record
protocol
elig
criteria
identifi
studi
report
supplementari
tabl
three
studi
could
obtain
although
result
studi
bass
et
al
report
elsewher
enabl
inclus
french
n
german
n
korean
n
record
screen
singl
review
lack
multilingu
collabor
studi
characterist
summar
supplementari
tabl
three
systemat
review
met
protocol
elig
criteria
data
patient
case
studi
case
seri
casecomparison
studi
prospect
cohort
includ
identifi
observ
studi
publish
studi
patient
receiv
clinic
diagnosi
influenzaassoci
pneumonia
spanish
influenza
infect
unclear
whether
studi
recruit
patient
secondari
bacteri
pneumonia
sixteen
observ
studi
met
protocol
elig
criteria
publish
four
studi
report
outcom
patient
infect
avian
influenza
studi
report
outcom
patient
infect
influenza
studi
report
outcom
patient
sar
clinic
statu
patient
time
treatment
administr
vari
concomit
treatment
comorbid
convalesc
plasma
use
observ
studi
sarscov
influenza
avian
influenza
infect
supplementari
tabl
spanish
influenza
infect
observ
studi
use
convalesc
plasma
use
convalesc
serum
supplementari
tabl
studi
use
hyperimmun
immunoglobulin
met
protocol
elig
criteria
use
sham
treatment
placebo
report
two
systemat
review
low
risk
bia
wherea
one
moder
low
risk
bia
across
domain
tabl
data
extract
judg
moder
sourc
bia
systemat
review
search
strategi
also
moder
sourc
bia
systemat
review
grey
literatur
nonpeerreview
sourc
consid
risk
bia
outcom
singl
prospect
cohort
studi
consid
moder
tabl
lack
random
treatment
alloc
may
introduc
systemat
error
viral
load
outcom
high
risk
bia
incomplet
followup
patient
figur
summar
risk
bia
assess
outcom
observ
studi
studi
report
outcom
either
moder
risk
outcom
moder
high
risk
select
bia
outcom
major
studi
lack
compar
group
studi
high
high
risk
report
bia
suggest
observ
studi
data
includ
moder
high
risk
bia
three
studi
assess
risk
bia
present
insuffici
data
tabl
summar
narr
synthesi
supplementari
tabl
show
result
individu
studi
includ
allcaus
mortal
outcom
metaanalys
sensit
analys
assess
public
bia
viral
etiolog
prove
unfeas
due
pauciti
suitabl
data
data
avail
address
studi
question
relat
organ
failur
sepsi
hospit
readmiss
recurr
sever
diseas
tabl
supplementari
summar
observ
studi
moder
high
risk
bia
report
improv
mortal
patient
receiv
variou
dose
convalesc
plasma
retrospect
casecomparison
studi
show
cfr
reduct
plasma
treatment
reach
statist
signific
absolut
reduct
cfr
ci
p
second
studi
compar
group
describ
cluster
case
sarscov
infect
patient
receiv
convalesc
plasma
surviv
absolut
reduct
cfr
ci
p
three
small
studi
report
treatment
patient
death
case
seri
cheng
et
al
report
cfr
patient
follow
treatment
supplementari
tabl
within
seri
subgroup
analysi
patient
found
treat
pcrposit
seroneg
sarscov
like
discharg
within
day
admiss
seroposit
time
plasma
infus
vs
p
subgroup
analysi
patient
found
receipt
convalesc
plasma
treatment
day
onset
symptom
improv
likelihood
discharg
within
day
admiss
vs
p
remain
signific
adjust
age
viral
statu
time
administr
lactat
dehydrogenas
level
suggest
earli
treatment
convalesc
plasma
may
benefici
howev
alloc
treatment
mostli
base
physician
decis
avail
plasma
studi
high
risk
bia
four
observ
studi
systemat
review
report
data
sever
case
influenza
infect
treat
convalesc
plasma
tabl
supplementari
tabl
hung
et
al
perform
prospect
cohort
studi
patient
receiv
singl
dose
convalesc
plasma
neutral
antibodi
titer
univari
analysi
show
signific
absolut
reduct
cfr
ci
p
treatment
multivari
analysi
also
show
signific
reduct
rel
risk
mortal
ci
p
although
factor
adjust
clearli
state
group
receiv
treatment
neuraminidas
inhibitor
steroid
supplementari
tabl
nonrandom
studi
moder
risk
bia
small
studi
chan
et
al
moder
risk
bia
report
exclus
patient
receiv
extracorpor
membran
oxygen
ecmo
show
nonsignific
absolut
reduct
ci
cfr
convalesc
plasma
treatment
case
seri
high
risk
bia
patient
receiv
convalesc
plasma
nonsignific
absolut
reduct
ci
p
cfr
observ
supplementari
tabl
three
case
report
report
recoveri
among
patient
treat
convalesc
plasma
dose
convalesc
plasma
vari
across
studi
neutral
antibodi
titer
report
case
studi
high
moder
risk
bia
patient
given
therapi
concomitantli
includ
steroid
antivir
could
influenc
report
clinic
effect
systemat
review
metaanalysi
luke
et
al
show
treatment
convalesc
plasma
serum
blood
associ
signific
absolut
reduct
ci
pool
cfr
statist
heterogen
low
although
intervent
clinic
heterogen
studi
includ
metaanalysi
report
use
convalesc
whole
blood
howev
studi
contribut
patient
treatment
group
time
treatment
record
patient
receiv
earli
treatment
day
pneumonia
onset
cfr
compar
treat
later
studi
convalesc
serum
report
compar
group
report
absolut
reduct
cfr
treatment
reduct
ci
one
ci
reduct
latter
reach
statist
signific
p
remain
studi
observ
cfr
rang
treatment
supplementari
tabl
signific
absolut
reduct
cfr
observ
case
seri
case
receiv
convalesc
plasma
absolut
reduct
cfr
ci
p
studi
patient
treat
convalesc
plasma
report
cfr
major
studi
spanish
influenza
infect
found
high
risk
bia
due
use
archaic
research
method
risk
wartim
censorship
public
bia
post
hoc
metaanalysi
evalu
pool
data
compar
studi
studi
sarscov
infect
influenza
infect
avian
influenza
infect
spanish
influenza
infect
statist
signific
lower
risk
mortal
group
treat
convalesc
plasma
serum
pool
ci
p
figur
examin
funnel
plot
find
egger
test
show
evid
public
bia
sensit
analys
exclud
studi
case
demonstr
littl
variat
pool
chang
statist
heterogen
figur
metaanalysi
crude
cfr
treat
patient
reject
due
excess
statist
heterogen
sensit
analysi
exclud
studi
case
account
similarli
abandon
convalesc
plasma
treatment
associ
signific
increas
proport
sarscovinfect
patient
discharg
within
day
admiss
center
absolut
differ
ci
p
exclud
patient
comorbid
analysi
tabl
sarscov
infect
case
seri
report
patient
discharg
day
initi
therapi
significantli
earlier
among
patient
discharg
time
mean
number
day
symptom
onset
vs
p
studi
moder
high
risk
select
bia
confound
indic
casecomparison
studi
moder
risk
bia
report
signific
differ
length
hospit
stay
treatment
control
patient
sever
pandem
influenza
infect
requir
ecmo
tabl
retrospect
observ
studi
report
convalesc
plasma
treatment
made
nonsignific
reduct
length
time
spent
intens
care
unit
day
data
report
identifi
studi
significantli
lower
viral
load
treatment
observ
day
icu
admiss
subgroup
analysi
prospect
studi
moder
high
risk
bia
one
noncompar
studi
found
reduct
viral
load
treatment
advers
event
complic
report
treatment
nonsignific
benefit
follow
intervent
report
studi
compar
data
three
case
report
report
death
compar
data
report
length
hospit
stay
case
report
high
risk
bia
compar
data
report
one
case
report
high
risk
bia
cite
treatment
allow
discontinu
mechan
ventil
specif
antibodi
detect
day
day
treatment
case
report
high
risk
bia
compar
data
report
three
studi
report
reduct
viral
load
treatment
advers
event
complic
report
treatment
pool
absolut
reduct
ci
cfr
report
metaanalysi
low
risk
bia
pool
studi
includ
studi
use
convalesc
blood
subgroup
analys
suggest
earli
treatment
benefici
absolut
reduct
risk
mortal
rang
ci
ci
studi
high
risk
bia
ten
noncompar
studi
found
cfr
vari
data
report
identifi
studi
data
report
identifi
studi
data
report
identifi
studi
data
report
identifi
studi
three
studi
report
chill
increas
temperatur
sweat
infus
abbrevi
cfr
casefat
rate
ci
confid
interv
ecmo
extracorpor
membran
oxygen
icu
intens
care
unit
influenza
pandem
influenza
sarscov
sever
acut
respiratori
syndrom
coronaviru
studi
report
use
convalesc
plasma
except
studi
convalesc
serum
use
treat
spanish
influenza
infect
metaanalysi
studi
report
use
convalesc
blood
treat
spanish
influenza
infect
addit
data
pertain
individu
studi
includ
compar
data
present
avail
supplementari
materi
mechan
ventil
number
day
ecmo
patient
sever
pandem
influenza
infect
tabl
two
case
report
pandem
influenza
infect
avian
influenza
infect
also
suggest
convalesc
plasma
may
aid
clinic
improv
reduc
durat
mechan
ventil
identifi
limit
evid
relat
level
viral
antibodi
convalesc
plasma
treatment
studi
use
compar
high
risk
bia
peak
sarscov
antibodi
level
occur
day
follow
receipt
singl
dose
convalesc
plasma
healthcar
worker
tabl
howev
like
treatment
intraven
immunoglobulin
ribavirin
steroid
may
influenc
relationship
plasma
antibodi
level
case
report
patient
avian
influenza
infect
also
found
virusspecif
antibodi
appear
day
follow
administr
convalesc
plasma
sarscov
load
respiratori
tract
decreas
higher
rate
patient
receiv
convalesc
plasma
subgroup
analysi
patient
influenza
infect
prospect
cohort
studi
tabl
viral
load
significantli
lower
day
intens
care
unit
admiss
howev
high
risk
select
bia
outcom
concomit
treatment
includ
oseltamivir
zanamivir
corticosteroid
may
confound
result
studi
report
viral
load
becam
rapidli
undetect
blood
patient
sarscov
infect
respiratori
tract
specimen
patient
infect
influenza
treatment
similar
decreas
viral
load
serum
respiratori
tract
specimen
observ
case
avian
influenza
infect
viru
becom
undetect
day
initi
convalesc
plasma
treatment
case
day
treatment
initi
third
case
supplementari
tabl
studi
report
seriou
advers
event
studi
report
inform
treatment
complic
although
minor
complic
may
underreport
literatur
two
observ
studi
concern
sarscov
infect
report
treatment
caus
harm
administ
patient
one
studi
involv
influenza
infect
report
advers
event
observ
treatment
group
three
studi
involv
patient
influenza
report
minor
infus
complic
includ
chill
increas
temperatur
sweat
studi
patient
report
chill
seriou
complic
method
report
studi
reflect
period
conduct
studi
therefor
high
risk
bia
analys
suggest
convalesc
plasma
may
clinic
relev
impact
reduc
rate
mortal
viral
load
patient
sari
viral
etiolog
post
hoc
pool
metaanalysi
across
viral
etiolog
show
statist
signific
reduct
odd
mortal
among
treat
convalesc
plasma
serum
found
evid
seriou
advers
event
complic
due
therapi
limit
evid
reduct
use
critic
care
resourc
length
hospit
stay
interest
evid
surviv
benefit
earli
administr
recent
multicent
prospect
doubleblind
random
control
trial
compar
use
hyperimmun
immunoglobulin
deriv
influenza
convalesc
plasma
intraven
immunoglobulin
manufactur
pandem
patient
studi
receiv
treatment
within
day
symptom
onset
exclud
per
protocol
multivari
subgroup
analysi
demonstr
hyperimmun
immunoglobulin
protect
effect
ci
evid
studi
sarscov
infect
spanish
influenza
infect
show
surviv
benefit
follow
convalesc
plasma
treatment
within
day
day
symptom
onset
respect
find
suggest
earli
initi
treatment
may
critic
import
reduc
mortal
patient
sari
viral
etiolog
lack
highqual
studi
pauciti
volum
relev
literatur
limit
analys
observ
studi
predomin
case
report
seri
control
group
moder
high
risk
bia
find
commonli
high
risk
confound
indic
although
select
report
bia
may
favor
intervent
recruit
patient
clinic
deterior
moribund
would
bia
result
opposit
direct
adequ
methodolog
statist
measur
infrequ
use
control
bia
confound
identifi
numer
sourc
clinic
methodolog
heterogen
assur
spanish
influenza
infect
studi
includ
sinc
protocol
includ
hand
search
literatur
although
post
hoc
metaanalys
undertaken
help
inform
clinic
decis
make
theoret
rational
pool
mortal
data
differ
viral
etiolog
remain
fulli
establish
result
obtain
must
consid
experiment
interpret
appropri
level
caution
identifi
report
convalesc
plasma
use
patient
merscov
infect
evid
reduct
mortal
associ
convalesc
plasma
strongest
sar
influenza
infect
although
clinic
ration
consid
novel
therapi
critic
ill
patient
evid
maximum
benefit
convalesc
plasma
might
realiz
earli
initi
therapi
howev
mani
treatment
protocol
current
mention
convalesc
plasma
treatment
last
resort
treatment
consid
merscovinfect
patient
sari
ideal
administ
acut
center
abl
manag
potenti
treatmentrel
complic
transfusionrel
acut
lung
injuri
consid
precautionari
approach
limit
clinic
experi
administ
convalesc
plasma
patient
group
improv
knowledg
regard
mode
action
convalesc
plasma
virolog
immunolog
kinet
novel
respiratori
infect
caus
sari
merscov
need
would
help
clarifi
potenti
benefit
harm
treatment
identifi
optim
dosag
ascertain
whether
repeat
treatment
relev
factor
clinic
practic
random
control
trial
observ
studi
adopt
standard
minimum
data
set
need
better
evalu
convalesc
plasma
therapeut
option
merscov
infect
fulli
recommend
refin
made
current
use
current
recommend
earli
use
intern
sever
acut
respiratori
emerg
infect
consortium
current
develop
clinic
trial
protocol
investig
effect
passiv
immunotherapi
patient
sari
avail
evid
suggest
convalesc
plasma
like
reduc
mortal
sari
viral
etiolog
larger
treatment
effect
commenc
earli
symptom
onset
howev
base
predomin
lowqual
uncontrol
studi
review
support
use
convalesc
plasma
critic
ill
merscovinfect
patient
part
welldesign
clinic
trial
formal
evalu
thank
follow
review
convalesc
plasma
studi
group
evalu
nonenglishlanguag
articl
basi
protocol
elig
criteria
undertook
risk
bia
assess
data
extract
dr
ana
l
p
mateu
supplementari
materi
avail
journal
infecti
diseas
onlin
http
jidoxfordjournalsorg
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
